(MedPage Today) — A risk evaluation and mitigation strategies (REMS) program is no longer required for the thyroid cancer therapy vandetanib (Caprelsa), the FDA announced on Thursday.
The agency had required the safety program for vandetanib…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/117646
Author :
Publish date : 2025-09-25 20:21:00
Copyright for syndicated content belongs to the linked Source.
